<DOC>
	<DOC>NCT01732783</DOC>
	<brief_summary>This is a multicenter, observational prospective cohort study in France and Germany. Treatment centres with a focus on treating subjects with mCRC will be prospectively defined for potential inclusion in the study. Eligible subjects will be enrolled and have retrospective data collected from Baseline up to the point of enrolment. All subsequent chemotherapy cycles and Vectibix® doses will be recorded prospectively. Each subject will have data collected until approximately 30 days after the end of Vectibix® treatment, death, withdrawal of consent, loss to follow-up or up to 12 months from the first dose of Vectibix®, whichever occurs first.</brief_summary>
	<brief_title>Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Subject is ≥ 18 years of age at date of enrolment Histologically or cytologically confirmed carcinoma of colon or rectum Subject with metastatic carcinoma of colon or rectum Confirmed wildtype RAS status of tumour Subjects whose care will be managed primarily by the enrolling physician and/ or all records will be available Tumour assessment (ie, CT/MRI) within 12 weeks (84 days) prior to first Vectibix® infusion. Subjects treated with at least one infusion of Vectibix® in combination with chemotherapy a maximum of 84 days before entering study: firstline in combination with FOLFOX or secondline in combination with FOLFIRI in subjects who have received firstline fluoropyrimidinebased chemotherapy (excluding irinotecan) for treatment of wildtype RAS mCRC per approved prescribing information Subject or subject's legally acceptable representative has provided informed consent (for countries where required per local regulations) Subjects treated with Vectibix® in accordance with the current version of the SmPC Exclusion Criteria Ongoing or planned concurrent participation in any clinical study involving Investigational Product that has not been approved by the European Medicines Agency for any indication Ongoing or planned concurrent participation in any clinical study where the dosing of Vectibix® is determined by the protocol (participation in clinical trials on an approved drug and observational trials are permitted but these cannot mandate how mCRC should be treated)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Wild-type RAS</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Vectibix</keyword>
</DOC>